Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
Department of Ultrasound, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
Int Immunopharmacol. 2021 May;94:107416. doi: 10.1016/j.intimp.2021.107416. Epub 2021 Mar 3.
Immune escape and low response to immunotherapy are crucial challenges in present lung cancer treatment. In this study, we constructed a new immune-related classifier based on CXCL13/CXCR5, an important tumor microenvironment component and strongly related with the formation of tertiary lymphoid structures (TLSs) in tumor microenvironment. With the classifier, we divided patients into two main clusters and each cluster was further divided into subcluster (A1, A2, B1, B2, B3). In the later analysis, we noticed that patients in subcluster B3 had a distinct advantage over patients in A1 in survival time and immune infiltration, suggesting a more favorable response to immunotherapy. Moreover, we demonstrated the genetic and epigenetic regulation related to the subclusters and recovered four key differentially expressed genes (ERBB4, GRIN2A, IL2RA, CCND2). With several experiments, we verified the unique role of CCND2 in tumor metastasis and T cell apoptosis. Overexpressing CCND2 could significantly impair cancer cell abilities of migration and invasion and downregulate PD-1/PD-L1 signaling, which may be the cause of T cell apoptosis reduction. In the end, we constructed a regression risk model that could successfully predict ICI response. To sum up, our study established new stratification models that can successfully predict patient survival and response to ICI. And using integrative analysis of multi-omics data, four key DEGs were noticed, and CCND2, one of the four genes, was identified as a potential treatment target because of its effect in tumor metastasis and T cell apoptosis.
免疫逃逸和对免疫疗法的低反应是目前肺癌治疗的关键挑战。在本研究中,我们构建了一个基于 CXCL13/CXCR5 的新免疫相关分类器,这是肿瘤微环境中的一个重要组成部分,与肿瘤微环境中三级淋巴结构(TLSs)的形成密切相关。使用该分类器,我们将患者分为两个主要簇,每个簇进一步分为亚簇(A1、A2、B1、B2、B3)。在后续分析中,我们注意到亚簇 B3 的患者在生存时间和免疫浸润方面明显优于亚簇 A1 的患者,这表明他们对免疫疗法的反应更为有利。此外,我们还证明了与亚簇相关的遗传和表观遗传调控,并恢复了四个关键差异表达基因(ERBB4、GRIN2A、IL2RA、CCND2)。通过多项实验,我们验证了 CCND2 在肿瘤转移和 T 细胞凋亡中的独特作用。过表达 CCND2 可显著损害癌细胞的迁移和侵袭能力,并下调 PD-1/PD-L1 信号通路,这可能是 T 细胞凋亡减少的原因。最后,我们构建了一个可以成功预测 ICI 反应的回归风险模型。总之,我们的研究建立了新的分层模型,可以成功预测患者的生存和对 ICI 的反应。通过对多组学数据的综合分析,我们注意到了四个关键的差异表达基因,其中 CCND2 作为四个基因之一,由于其在肿瘤转移和 T 细胞凋亡中的作用,被确定为一个潜在的治疗靶点。